While recent molecular analyses found significantly enriched molecular driver alterations at distinct tumor sites such as KIAA1549::BRAF fusions in tumors of the posterior fossa or BRAF-V600E mutations in tumors involving the cerebral hemispheres, no particular hallmark alteration has been described in BS-pLGG [22, 26]. This evidence concerns the gene BRAF and neoplasm.